These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

517 related items for PubMed ID: 24898153

  • 1. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V, Porcaro G.
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [Abstract] [Full Text] [Related]

  • 2. The rationale of the myo-inositol and D-chiro-inositol combined treatment for polycystic ovary syndrome.
    Dinicola S, Chiu TT, Unfer V, Carlomagno G, Bizzarri M.
    J Clin Pharmacol; 2014 Oct; 54(10):1079-92. PubMed ID: 25042908
    [Abstract] [Full Text] [Related]

  • 3. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M, Nordio M, Pajalich R.
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [Abstract] [Full Text] [Related]

  • 4. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M, Proietti E.
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [Abstract] [Full Text] [Related]

  • 5. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
    Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A.
    Gynecol Endocrinol; 2007 Dec; 23(12):700-3. PubMed ID: 17952759
    [Abstract] [Full Text] [Related]

  • 6. Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
    Bizzarri M, Carlomagno G.
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1896-903. PubMed ID: 25010620
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G, Cappelli V, Di Sabatino A, Massaro MG, De Leo V.
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [Abstract] [Full Text] [Related]

  • 9. Myo-inositol vs. D-chiro inositol in PCOS treatment.
    Formuso C, Stracquadanio M, Ciotta L.
    Minerva Ginecol; 2015 Aug; 67(4):321-5. PubMed ID: 25670222
    [Abstract] [Full Text] [Related]

  • 10. Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
    Galletta M, Grasso S, Vaiarelli A, Roseff SJ.
    Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1212-4. PubMed ID: 22165685
    [Abstract] [Full Text] [Related]

  • 11. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial.
    Colazingari S, Treglia M, Najjar R, Bevilacqua A.
    Arch Gynecol Obstet; 2013 Dec; 288(6):1405-11. PubMed ID: 23708322
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
    Zhao H, Xing C, Zhang J, He B.
    Reprod Health; 2021 Aug 18; 18(1):171. PubMed ID: 34407851
    [Abstract] [Full Text] [Related]

  • 13. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G, Unfer V, Harrath AH, Bizzarri M.
    Gynecol Endocrinol; 2017 Jan 18; 33(1):1-9. PubMed ID: 27898267
    [Abstract] [Full Text] [Related]

  • 14. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome.
    Minozzi M, Costantino D, Guaraldi C, Unfer V.
    Gynecol Endocrinol; 2011 Nov 18; 27(11):920-4. PubMed ID: 21417594
    [Abstract] [Full Text] [Related]

  • 15. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
    Gateva A, Unfer V, Kamenov Z.
    Gynecol Endocrinol; 2018 Jul 18; 34(7):545-550. PubMed ID: 29309199
    [Abstract] [Full Text] [Related]

  • 16. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE, Unfer V.
    Gynecol Endocrinol; 2015 Jul 18; 31(7):501-5. PubMed ID: 26177098
    [Abstract] [Full Text] [Related]

  • 17. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
    Nestler JE, Jakubowicz DJ, Iuorno MJ.
    J Pediatr Endocrinol Metab; 2000 Jul 18; 13 Suppl 5():1295-8. PubMed ID: 11117673
    [Abstract] [Full Text] [Related]

  • 18. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.
    Costantino D, Minozzi G, Minozzi E, Guaraldi C.
    Eur Rev Med Pharmacol Sci; 2009 Jul 18; 13(2):105-10. PubMed ID: 19499845
    [Abstract] [Full Text] [Related]

  • 19. Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
    Stracquadanio M, Ciotta L, Palumbo MA.
    Gynecol Endocrinol; 2018 Jun 18; 34(6):495-501. PubMed ID: 29265900
    [Abstract] [Full Text] [Related]

  • 20. Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.
    Wojciechowska A, Osowski A, Jóźwik M, Górecki R, Rynkiewicz A, Wojtkiewicz J.
    Int J Mol Sci; 2019 Nov 18; 20(22):. PubMed ID: 31752081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.